leisure time -WSS

leisure time

author：leisure time 2025-09-30 16:28:41 - browse：3

The federal government is reforming methadone care for the first time in over two decades. But how far do the changes actually go?

To many methadone clinics, the Biden administration’s recent refresh of the rules governing opioid treatment programs represents an unprecedented opportunity to offer care that is more compassionate and responsive to patients’ needs. To many patient advocates, however, it simply nibbles around the edges.

The reality is likely somewhere in between: It will depend, in large part, on whether state-level regulators embrace the changes, and whether individual clinics actually implement them. In reform-oriented states, and at patient-centered clinics, the new rules could make a world of difference for people seeking addiction treatment.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： What PEPFAR has meant on the ground in Ukraine

hotspot

WSS

With measles on the rise, a personal story of a devastating disease

Anxious about a speech? A startup wants you to pop a minty cardiac drug

FDA needs staff influx to meet gene therapy needs, Marks says

Readers respond to H5N1 and livestock movements, and more

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

What causes an itch? Researchers may have solved the mystery

focus

leisure time

hotspot

Jerome Adams on the need for new antivirals for Covid

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Novavax promises a turnaround & Lilly roils the obesity market

Readers respond to H5N1 and livestock movements, and more

In age of alternative facts, a scholarly course on calling out crap

After sickle

Continuity nursing helped my family in our darkest PICU moments

Teach medical students about patients with intellectual disabilities

Dobbs anniversary: the lost opportunity of abortion as health care

Case highlights the risks of experimental stem cell therapy

focus

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Cytokinetics CEO stresses company can launch heart drug on its own

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

NVIDIA and Google execs on the future of AI and drug discovery

STAT letters to the editor on burnt

focus

hotspot

hotspot

entertainment